cls-3 Antibody
Description
Class-3 Neutralizing Antibodies in Viral Immunity
Antibodies targeting class-3 epitopes on the SARS-CoV-2 spike protein are critical for broad-spectrum viral neutralization. These antibodies bind to conserved regions of the receptor-binding domain (RBD), enabling activity against evolving variants like Omicron .
Key Features of Class-3 Antibodies:
Example: LY-CoV1404 (bebtelovimab), a class-3 antibody, retained potency against all Omicron subvariants until its emergency use authorization was revoked due to emerging resistance in late 2023 .
Claudin-3 (CLDN3)-Targeted Antibodies
Claudin-3 is a tight junction protein overexpressed in epithelial cancers. While not termed "cls-3," antibodies against Claudin-3 are widely used in oncology research .
Research Applications of Anti-Claudin-3 Antibodies:
-
Flow Cytometry: Detects Claudin-3 in prostate cancer cell lines (e.g., PC-3) with high specificity (Figure 1A) .
-
Immunohistochemistry: Localizes Claudin-3 in colon and ovarian cancer tissues (sensitivity: 1:100 dilution) .
-
Western Blot: Identifies 20–23 kDa bands corresponding to full-length and processed Claudin-3 isoforms .
Clinical Relevance:
-
Prognostic marker for metastatic colorectal cancer (5-year survival correlation: p < 0.01) .
-
Therapeutic target in antibody-drug conjugates for ovarian cancer .
CSL311: A β Common Receptor-Targeting Antibody
Though not named "cls-3," CSL311 is a high-affinity monoclonal antibody (KD: 1.2 pM) that inhibits IL-3, GM-CSF, and IL-5 signaling via the shared βc receptor (CD131). Preclinical data show:
-
Eosinophil Suppression: IC₅₀ of 0.8 nM in allergic asthma models .
-
Structural Mechanism: X-ray crystallography reveals binding to the cytokine interaction site (PDB: 5DWU) .
LAG-3-Targeted Antibodies in Immunotherapy
LAG-3 inhibitors like TSR-033 (IgG4κ) enhance antitumor T-cell activity when combined with PD-1 blockers. Phase I trials demonstrate:
